Introduction
There is considerable pharmaceutical interest in the use of synthetic antisense oligodeoxynucleotides (ODNs) to specifically interfere in the process of gene expression. [1] Antisense ODNs are short synthetic DNA polymers (or chemical analogues) that are complementary to a target RNA molecule. They are designed to halt a biological event, such as translation or splicing. [2] Antisense ODNs have been pursued as a major class of new pharmaceuticals for a variety of human diseases, including cancer and viral infections. [3] After several decades of research and development, so far very few nucleic acid therapeutics have been approved for human use: Fomivirsen (Vitravene) is an antisense ODN composed of 21 phosphorothioate-linked nucleosides which was approved for the treatment of retinal inflammation caused by cytomegalovirus, but it was later withdrawn from the market. [4] Similarly Macugen (pegaptanib sodium injection), a 28-nucleotide RNA aptamer conjugated to 20 kDa polyethylene glycol targeted to heparin binding domain of VEGF165, was approved for the treatment of wet age-related macular degeneration. [5] Recently, the US Food and Drug Administration has approved a new lipidlowering drug: Mipomersen (marketed as Kynamro by Genzyme, Cambridge, MA, USA).
This drug is an antisense molecule based on 2′-O-(2-methoxy) ethyl-modified ribose ODN developed against ApoB100 mRNA to treat the homozygous familial hypercholesterolemia. [6] However, the clinical success achieved so far with ODNs has not been satisfactory; some of the major impediments have been recognised as their instability against nucleases, poor delivery or uptake by cell targeted, and off-target effects or toxicity among others. To address these limitations, a variety of different chemical modifications in the ODN backbone have been introduced. ODNs are quickly degraded by nucleases in both in vitro and in vivo contexts, increasing their nuclease resistance is a major issue for the development of ODN based in vivo applications. They can be degraded by both endoand exonucleases. [7] One of the most straightforward modifications made to an ODN to increase the resistance to nuclease degradation, is to replace a non-bridging oxygen on the phosphate backbone with sulphur, producing a phosphorothioate (PS) linkage [8] ( Figure 1B ). It has been later learned that RNA/DNA hybrids containing this modification are also substrate for RNase H, [9] which has been shown to be the molecular inhibition mechanisms of many antisense ODN by promoting the degradation of the target RNA.
Methylation of the 2' position of the ribose (2'-OMe) is already a standard modification to yield highly nuclease resistant ODNs. [10] Numerous efforts have also been made to improve the pharmacokinetic and pharmacodynamic properties of antisense ODNs, and very importantly to overcome negative or undesired effects by covalently attaching, conjugating, chemical groups or molecules that may provide new properties to the ODNs. [11] The potential application of conjugated ODNs is not only limited to therapeutics but also in diagnostics and nanotechnology. Conjugation of ODNs with cationic compounds, such as poly-(L)-lysine [12] or polyamides, [13] lipophilic conjugates, such as cholesterol, [14] attachment of long chain alcohols, [15] phospholipids, [16] aromatic compounds, [17] as well as polyethylene glycol [18] have been successfully tested to pursue a more efficient ODNs delivery to specific target cells which represent an important limitation of in vivo ODN application. We have previously reported an improvement in the cell uptake of ODNs containing a terminal glucose unit linked through a long tetraethylene glycol spacer or just one doubler dendrimer in HeLa and U87-CD4 + -CXCR4 + human cells. [19] Such modifications also contribute to the stability of oligoribonucleotides against 5'-end exonuclease degradation. [20] The phosphorothioate antisense ODN GEM 91 [21] , registered as trecovirsen, complementary to the initiation codon of the gag ORF of the HIV-1 RNA (positions 324-348) [22] ( Figure 1A ) was shown to yield a potent anti-HIV activity in cell culture. [21, 23] Surprisingly, a transient increase in HIV-1 replication was reported in vivo when GEM 91 was administered by continuous i.v. infusion for 8 days in a blinded dose escalation study. [24] To test whether this was a side-effect induced by the CpG-like motifs present in the GEM 91 ODN, a new antisense ODN (GEM 92) lacking these motifs was assayed.
GEM 92 ODN resulted in a loss of this viral replication enhancement induced in vivo by the GEM 91, but exhibited an unacceptable anti HIV-1 activity. [25] This result is in good agreement with those previous observations that ODNs containing CpG motifs mimic properties of bacterial CpG DNA activating immune response through TLR9 (Toll-like receptor 9) [26] and that the TLR9 ligand (CpG DNA in that study) promotes the HIV replication in ex vivo HIV-1 transgenic mouse spleen cells. [27] Therefore, it is possible that an increase in HIV-1 copy number following administration of GEM 91 was due to activation of TLR9.
In the current work we have analysed the biological properties and anti-HIV-1 activity of the conjugation of a glucose residue at the 5'-end of the GEM 91 (Gluc-GEM 91) resulting in a significant reduction of the immune response activation while maintaining its antiviral activity and biochemical properties.
Results

Stability of 5' glucose conjugated ODNs in serum
To analyse whether ODNs modified at the 
Anti-HIV-1 activity of 5' glucose conjugated ODNs
The effect of the 5' glucose conjugation in the antiviral activity of the GEM 91 (PS) was tested using two different experimental strategies. Firstly, human glioblastoma U87-CD4 + -CXCR4 + cells were cotransfected with 500 pmol (1 µM) of ODN and 100 ng of pNL4-3
plasmid, which contains a full infectious provirus, HIV-1 NL4-3 . [30] Viral particles production was measured at two days post-transfection as p24 antigen abundance in the cellular supernatant as described in Experimental Section. This represents an experimental model of a post-integrative viral inhibition assay. No viral particles were detected in the cell cultures transfected with either of the phosphorothioate modified ODN; GEM 91 (PS) or Gluc-GEM 91 (PS) ( Figure 5A ). These potent inhibitions are consistent with the previously reported data. [21, 23] Similarly, a highly efficient inhibition was seen in the presence of GEM 91 (PO) or Gluc-GEM 91 (PO) (86 and 84% inhibition, respectively). Potent inhibition was also observed at an ODN concentration as low as 0.02 μM (data not shown).
Secondly, ODNs were tested for their ability to inhibit HIV-1 replication in a viral preintegrative model. For this purpose HIV-1 infected U87-CD4 + -CXCR4 + cell cultures were treated with 1 µM ODN and p24 antigen was measured as described in Experimental Section. A potent HIV-1 particles production inhibition was observed with GEM91 (PS) (90% inhibition) and the glucose conjugated derivative Gluc-GEM 91 (PS) (91% inhibition) ( Figure 5B). However, little inhibitory effect was observed in GEM 91 (PO) and Gluc-GEM 
Long-term protection against HIV-1 infection in Jurkat cells by Gluc-GEM 91 (PS)
To compare the long-term efficacy of GEM 91 (PS) with that of Gluc-GEM 91 (PS), 
Conjugation of glucose at the 5'-end of GEM 91 does not increase cellular uptake
In order to examine whether the glucose conjugation increased the cellular ODN uptake, we compared the cellular uptake of 3' end 32 applications. In particular synthetic ODN containing unmethylated cytosine-guanosine motifs (CpG) have been described as potent immunoestimulatory. [31] It is important to note that GEM 91 ODN contains a CpG dinucleotide located closer to the 5'-end and it has been shown that such dinucleotide located closer to the 5'-end is critical for induction of the immune responses [32] and the blockage of the ODN 5′ end results in loss of the immunostimulatory effect. [33]
Discussion
A potent antisense drug should be highly resistant to nucleases, to exhibit high affinity for the target mRNA and favourable pharmacokinetics. These properties can be achieved by Natural phosphodiester ODNs are quickly digested by nucleases, it appears that the bulk of biologically significant nucleolytic activity in serum is 3' exonuclease, [7b] however within the cell nucleolitic activity is both 3' and 5' exonuclease. [7a] As expected, our results indicated that in cell culture medium containing heat inactivated serum GEM 91 (PS) and Gluc-GEM 91 (PS) were more stable than GEM 91 (PO) and Gluc-GEM 91 (PO). We found no differences in stability between the glucose conjugated and unconjugated ODNs in serum. However, these ODNs attached to glucose in its 5'-end could be even more stable in vivo than unconjugated ODNs since modification at the 5'-end may protect them from 5' exonuclease digestion in vivo. Our results also indicated that the 5' glucose conjugation did not lead to an improvement of the ODN cellular uptake (Figure 8 ). These results mostly agree with previous observations reporting that cellular uptake was hardly improved by the conjugation of glucose monomers just when linked through a long tetraethylene glycol spacer, [19] showing that a 15 to 18 atoms distance between the glucose and the ODN should be kept to achieve a more efficient cellular internalization.
This observation should be considered for further optimization of antisense Gluc-ODNs.
The antiviral activity of GEM 91 (PO), Gluc-GEM 91 (PO), GEM 91 (PS) and Gluc-GEM 91 (PS) was tested in acutely HIV-1 infected cells using two different CD4 + cell lines, Jurkat and U87-CD4 + -CXCR4 + , which are susceptible to HIV-1 infection and allow a high level of viral replication. Our results showed that in contrast to the PS derivatives, the GEM 91 (PO) and Gluc-GEM 91 (PO) exhibited antiviral activity only when they are delivered by transfect agents to culture cells ( Figure 5A ). The most likely explanation is that GEM 91
(PO) and Gluc-GEM 91 (PO) are not resistant enough in the cell or the culture medium and the potential problem of nuclease degradation of the ODNs may conceivable be overcome by delivering them using transfection agents, entering within the nucleus more efficiently and therefore resulting in significant inhibition of viral particles production. It is remarkable that the conjugation of glucose at the 5′-end of GEM 91 (PS) or GEM 91 (PO) resulted in similar anti HIV-1 activity to that of its unconjugated molecule, indicating that the glucose residue at the 5′-end does not result in a modification of the mechanism of action of the ODNs challenging their antiviral activity. The lack of correlation between the in vitro dimerisation effects and the anti-HIV activities in cell culture assays clearly indicate that the latest is mainly due to the ODNs interference with other steps of the HIV-1 particles production process. ODNs cell induced toxicity is also an important factor that could lead to an overestimation of the antiviral ODN effect when assessing it by a p24 assay. In the conditions used in this study we have not detected any cytotoxicity as monitored by trypan blue dye exclusion (data not shown).
Previous studies have demonstrated that differences in immunostimulatory activity of 3′-and 5′-conjugates are due to the requirement of 5′-end accessibility for TLR9-mediated immune responses, but not as a result of their differences in cellular uptake, as both types of conjugates are taken up by cells to the same extent. [33] Further, these studies showed that conjugation of a mono, di, tetra, or oligonucleotide through 5′-5′ linkage or a fluorescein moiety, but not a phosphorothioate group, at the 5′-end significantly reduces TLR9-mediated immune response. [33] These results together with our present study suggest that an accessible 5′-end of ODN is required for TLR9-mediated immune responses and conjugation of moieties like peptides or glucose at the 5′-end of ODN results in loss of TLR9-mediated immune responses. On the other hand, it is likely that TLR9 activated immune response by the CpG motif in GEM 91 was responsible for the observed increases in viral load, [24] being biologically active even in ODN (PS). Our data clearly indicate that conjugation of glucose to the 5'-end of GEM 91 (Gluc-GEM 91) decreases immune response through TLR9 while it is taking up well by cells, hybridizes to its complementary nucleic acid target and maintain an unaffected anti HIV-1 activity.
Presently several antisense ODN (PS) containing CpG motifs are in human clinical trials for various diseases and indications. Our data suggests that conjugation of a molecule of glucose at the 5'-end could act as "immunosupressor" and thereby reduce toxic effects while still allowing proper binding to its target sequence, and biological activity.
In conclusion, the results presented here demonstrate that the 5' Gluc-ODN conjugation decreases the innate cellular response associated to the recognition of the 5'-end in CpG
ODNs, and therefore the undesired side effects associated to such response, at the time that does not interfere with the biological activity of the ODNs, proposing these conjugates are of value as antisense agents.
Experimental Section
ODNs and RNA synthesis
All ODNs were synthesized on 1 μmol scale using standard phosphoramidite chemistry.
GEM 91 ODN series used in this study were: GEM 91 (PO) 5'-CTCTCGCACCCATCTCTCTCCTTCT-3', which corresponds to the unmodified ODN;
Gluc-GEM 91 (PO), contained a glucose molecule covalently linked to its 5'-end; GEM 91
(PS) and Gluc-GEM 91 (PS) are the corresponding totally substituted phosphorothioate
ODNs. The 5' glucose conjugation was obtained as previously described. [36] The Random- [30] using the primers 5'-T7pNL4-3: 5'-TAATACGACTCACTATAGGGTCTCTCTGGTTAG-3' (T7 promoter sequence is indicated in bold), and 3' pNL4-3-gag 5'-GCTTAATACCGACGCTCTC-3'. HIV-1 5'-UTR genomic RNA fragment was obtained by in vitro transcription as previously described. [37] Antisense ODN stability assay TBE and 10%, glycerol), and snap-frozen on dry ice immediately. Samples were thawed and run on a 15% nondenaturing 1X TBE polyacrylamide gel at 100 V for 75 min and stained with a 1:10000 dilution of GelStar® Nucleic Acid Gel Stain (Lonza, Rockland, ME) in 1X TBE buffer for 30 min. Gels were scanned using Typhoon 9400
Phosphorimager/Fluorescence Imager and quantified with Image Quant software 5.2 © (GE Healthcare; Chalfont ST. Giles, UK).
In vitro RNase H cleavage assay
RNase H digestion assays were essentially as described in Reyes-Darias et al. (2012) . formamide loading buffer and loaded onto a 7 M urea 6% polyacrylamide denaturing gel in 1X TBE buffer. Electrophoresis was followed at 20 mA for approximately 90 min, and gels were dried and analysed as described above.
Inhibition of HIV-1 RNA dimerisation by ODNs
HIV-1 RNA dimerisation reactions were performed as previously described [38] in the presence or absence of 100 pmol of unlabelled antisense ODN. Samples were resolved in 1% agarose gels in 1X TBM buffer (0.5X Tris-borate, 0.1 mM MgCl 2 ), and gels were visualized and quantified as described above. The dimerisation efficiency was calculated as [dimmer x 100/(dimer + monomer)]. Data are expressed at the mean ± standard deviation of two independent experiments.
Cell culture
The human glioblastoma U87-CD4 + -CXCR4 + cell line, stably expressing CD4 and the chemokine receptor CXCR4, was grown in DMEM supplemented with 10% FBS, 50 μg/mL gentamycin (Sigma Chemical Co. St Louis, MO), 1 mM sodium pyruvate (Sigma), 2 mM Lglutamine (Sigma), 300 μg/mL G418 (Sigma) and 1 μg/mL puromycine (Sigma). The human embryonic kidney HEK 293T cell line was maintained in DMEM supplemented with 10% FBS, 100 μg/mL streptomycin (Sigma), 4 mM L-glutamine and 1 mM sodium pyruvate. Human Burkitt lymphoma cell line Namalwa was maintained as suspension culture in RPMI 1640 medium supplemented with 10% FSB, 2 mM L-glutamine and 50 μg/mL gentamycin (Sigma). Cells were maintained at 37ºC in a humidified atmosphere with 5% CO 2 .
HIV-1 inhibition of viral particles production assays
For post-integrative viral inhibition assay U87-CD4 + -CXCR4 + , 1x10 5 cells/well were seeded in 0.5 mL of DMEM in 24-well culture plates and incubated at 37°C for 24 h before co-transfection. The following day cells were co-transfected with 500 pmol (1 µM) of ODN and 100 ng of pNL4-3 plasmid complexed together with 1 μL Fugene HD (Roche;
Mannheim, Germany). After 6 hours, the transfection mixture was replaced with 1 mL of fresh growth medium, and cells were further incubated at 37°C for two days before p24 determination.
For pre-integrative viral inhibition assays, U87-CD4 + -CXCR4 + cells were seeded in 0. The IL-10 RT-PCR was done with primers: forward, 5′-TCGGTGATGGTCTCTTCCTC-3′
and reverse, 5′-CGTCGCAATAAACCGTACCT-3′ amplifying a 237-bp fragment. Gene expression was normalised to the GAPDH expression levels. The calibrator sample in realtime PCR was the cDNA from untransfected Namalwa cells. Data was analysed using the comparative cycle threshold (Ct) method, as described. [39] Figure Legends 
